四環醫藥(00460.HK)：拒絕非法走私產品，倡導中國醫美“正能量”
2021年6月10日，國家衞健委牽頭八部委發佈了《關於印發打擊非法醫療美容服務專項整治工作方案的通知》。2021年8月9日，人民日報刊發了題為“醫療美容要最佳效果也要防不良後果”文章。文章表明，整治的目的只有一個，即高屋建瓴，加強監管，嚴厲打擊非法醫療美容服務，營造風清氣正的醫美大環境，樹醫美新風，並促其健康發展。
進口產品樂提葆(注射用A型肉毒毒素)是由韓國Hugel公司生產的一款醫美產品。知名國際投資機構貝恩資本為韓國Hugel公司控股股東。四環醫藥(00460.HK)旗下北京渼顏空間生物醫藥有限公司，作為該產品的中國總代理，長期致力於打造中國醫美領軍企業，並在2020年10月從中國國家藥品監督管理局獲得該產品的正式批准，成為第一家韓國該類產品獲得批准的醫藥。四環醫美作為中國醫美“正能量”的一份子，積極響應八部委“打擊非法醫療美容服務”專項活動，責無旁貸。
四環醫美，與眾多醫美產品生產企業一樣，是中國醫美“正能量”的倡導者，但也是非法渠道產品的受害者。非法渠道的所謂醫美產品，不僅侵害求美者的身心，而且嚴重阻礙了中國醫美健康持續發展之路。更與我黨提出的“人民對美好生活的嚮往，就是我們的奮鬥目標。”背道而馳。
四環醫美，將積極主動配合相關政府職能部門，將追根溯源，為嚴厲打擊非法產品走私，非法產品製售，非法產品運輸，提供有力證據。四環醫美也會努力敦促韓國相關企業尊重和配合中國政府的政策、嚴格監管出口渠道、共同防範打擊走私，確保韓國醫美產品的合法性，保障兩國消費者的利益。
四環醫美，將積極與中國整形美容協會行業發展與自律委員會合作，積極參與“中國醫美”小程序，公佈採購產品的合規醫美醫療機構名單，並定期更新，聯合推廣產品的“掃碼驗真”功能。
四環醫美，將與關注中國醫美的各界同行一起，為營造中國醫美“真”“正”的大環境不懈努力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
